GlassScriptPhysician profile
Diana Yao
NPI 1588678833
$8,686.44
in general payments reported to CMS, 2019-2025
42 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $342 · 2021: $828 · 2022: $1,602 · 2023: $1,644 · 2024: $1,511 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,725 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,724.74 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,353.89 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,319.97 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Madrigal Pharmaceuticals | $549.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $474.04 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Merck Sharp & Dohme LLC | $420.27 | 2019-2024 | Dificid |
| Genzyme Corporation | $367.54 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $278.34 | 2024 | Iqirvo |
| Pfizer INC. | $244.16 | 2019-2025 | |
| Celgene Corporation | $241.00 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $207.23 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $203.51 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $171.16 | 2019-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $157.21 | 2019-2023 | Entyvio, Gattex |
| Qol Medical, LLC | $156.88 | 2022-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $142.85 | 2025 | Barrx |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $139.33 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $119.92 | 2023 | Shingrix |
| Ironwood Pharmaceuticals, INC | $119.83 | 2019-2024 | Linzess |
| Fresenius Kabi USA, LLC | $119.32 | 2023 | |
| Shionogi INC | $115.63 | 2019 | |
| Ferring Pharmaceuticals INC. | $93.06 | 2019-2025 | Rebyota |
| Daiichi Sankyo INC. | $66.06 | 2019-2021 | |
| Organon LLC | $63.56 | 2022-2023 | Hadlima |
| Aimmune Therapeutics, INC. | $61.90 | 2025 | Vowst, Zenpep |
| Evoke Pharma, INC. | $43.02 | 2022 | |
| Lucid Diagnostics INC. | $41.92 | 2022 | |
| Shield Therapeutics INC | $35.80 | 2023-2024 | Accrufer |
| Conmed Corporation | $34.69 | 2025 | Conmed Hemostasis, Conmed Dilation |
| Amgen INC. | $31.94 | 2020 | |
| Lilly USA, LLC | $31.21 | 2024 | Omvoh |
| Alnylam Pharmaceuticals INC. | $29.63 | 2025 | Givlaari |
| Neurocrine Biosciences, INC. | $26.46 | 2024 | Ingrezza |
| Braintree Laboratories, INC. | $26.42 | 2021-2022 | |
| Allergan, INC. | $26.17 | 2019 | |
| Sandoz INC. | $25.23 | 2023 | Hyrimoz |
| Alcresta Therapeutics, INC. | $24.32 | 2024 | Relizorb |
| Gilead Sciences, INC. | $23.90 | 2023 | |
| Nestle Healthcare Nutrition INC. | $22.52 | 2023 | |
| Exact Sciences Corporation | $22.09 | 2023 | Cologuard Collection Kit |
| Celltrion USA INC. | $19.97 | 2024 | Zymfentra |
| Ucb, INC. | $17.98 | 2019 | |
| Redhill Biopharma INC. | $16.59 | 2024 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.